Bicyclic RIP-1 Kinase Inhibitors for Controlling Inflammatory Necrosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory diseases related to RIP-1 kinase activity are inadequate, as existing compounds do not effectively inhibit the kinase, leading to uncontrolled inflammatory responses.
Innovation Solution
Development of bicyclic compounds represented by formula (I) or their stereoisomers or pharmaceutically acceptable salts, which specifically target and inhibit RIP-1 kinase activity, thereby modulating inflammatory signaling pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing compounds are used for RIP-1 kinase inhibition, then treatment for inflammatory diseases is provided, but the compounds do not effectively inhibit the kinase, leading to uncontrolled inflammatory responses
Solution Approach 1:
The patent applies parameter changes by systematically varying molecular parameters of the compound structure (formula I) to optimize RIP-1 kinase inhibition. The invention identifies specific structural parameters (ring A, ring B, substituent patterns, stereochemistry) that when modified within defined ranges, produce compounds with enhanced inhibitory efficacy against RIP-1 kinase, thereby resolving the inadequacy of existing compounds
Solution Approach 2:
The patent applies local quality by introducing specific functional groups and substituent patterns at particular positions in the bicyclic core structure. Different substituents (halogens, alkyl groups, heteroatoms) are placed at specific locations on rings A and B to create localized interactions with the kinase active site, thereby achieving effective inhibition while maintaining overall molecular stability
2Reliability
If bicyclic compounds of formula (I) are developed to specifically target RIP-1 kinase, then inhibitory effects on programmed cell necrosis are achieved, but the structural complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the molecule into distinct functional segments: a core bicyclic structure (rings A and B), substituent groups (R1, R2, R3, R4), and linker elements. This modular segmentation allows systematic optimization of each segment's contribution to kinase binding while managing overall molecular complexity through defined structural rules
Solution Approach 2:
The patent applies universality by designing a bicyclic core structure that can accommodate multiple substituent variations while maintaining the fundamental mechanism of RIP-1 kinase inhibition. The core structure serves multiple functions: providing structural rigidity, enabling diverse substituent attachment, and maintaining binding affinity, thereby managing complexity through a universal scaffold
Data Source
AI summary
A compound represented by formula (I), isomers or pharmaceutically acceptable salts thereof, and application thereof in the preparation of drugs for treating diseases related to RIP-1 (receptor interacting protein) kinase.